JS 026
Alternative Names: JS-026Latest Information Update: 28 Jan 2025
At a glance
- Originator Shanghai Junshi Biosciences
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(Combination therapy, In volunteers, In adults) in China (IV, Injection)
- 28 Jan 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(Monotherapy, In volunteers, In adults) in China (IV, Injection)
- 08 Dec 2022 Shanghai Junshi Bioscience completes a phase I trials in COVID-2019 infections (Monotherapy, Combination therapy, In volunteers) in China (IV) (NCT05167279)